The availability of a serum biomarker with greater diagnostic accuracy for NAFLD-HCC than AFP may influence the way in which high-risk NAFLD/NASH patients are screened as they comprise a significant proportion (between 30–40%) of the adult population in affluent nations [21, 22]. This evidence concerns the gene AFP and metabolic dysfunction-associated steatohepatitis.